A Multi-center, Randomized, Sham-controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in Subjects With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy

Trial Profile

A Multi-center, Randomized, Sham-controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in Subjects With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs SB 101 (Primary)
  • Indications Acute kidney injury
  • Focus Adverse reactions
  • Sponsors Sentien Biotechnologies
  • Most Recent Events

    • 12 Jul 2017 Patient recruitment is expected to continue into 2018 according to a Portage Biotech media release.
    • 15 May 2017 Status changed from not yet recruiting to recruiting.
    • 09 May 2017 Planned initiation date changed from 1 Mar 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top